Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2010-022782-99
    Sponsor's Protocol Code Number:Q4881g
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2012-01-12
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2010-022782-99
    A.3Full title of the trial
    A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF XOLAIR® (OMALIZUMAB) IN PATIENTS WITH CHRONIC IDIOPATHIC URTICARIA (CIU) WHO REMAIN SYMPTOMATIC DESPITE ANTIHISTAMINE TREATMENT (H1)
    ESTUDIO MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO DE BÚSQUEDA DE DOSIS EN FASE III PARA EVALUAR LA EFICACIA Y SEGURIDAD DE XOLAIR® (OMALIZUMAB) EN PACIENTES CON URTICARIA IDIOPÁTICA CRÓNICA (UIC) QUE PERMANECEN SINTOMÁTICOS A PESAR DEL TRATAMIENTO CON ANTIHISTAMÍNICOS (H1)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A 40 week long study using Xolair to treat patients with Chronic Itch/Hives without known cause.
    Estudio de 40 semanas de duración con Xolair para tratar a pacientes con prurito/ronchas crónicas sin causa conocida.
    A.3.2Name or abbreviated title of the trial where available
    ASTERIA I
    A.4.1Sponsor's protocol code numberQ4881g
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT01287117
    A.7Trial is part of a Paediatric Investigation Plan Yes
    A.8EMA Decision number of Paediatric Investigation PlanP/133/2010
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorGenentech, Inc.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportGenentech Inc
    B.4.2CountryUnited States
    B.4.1Name of organisation providing supportNovartis
    B.4.2CountrySwitzerland
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationGenentech Inc
    B.5.2Functional name of contact pointKristi Miller
    B.5.3 Address:
    B.5.3.1Street Address1 DNA Way
    B.5.3.2Town/ citySouth San Francisco
    B.5.3.3Post codeCA 94080-4990
    B.5.3.4CountryUnited States
    B.5.4Telephone number1650225 1000
    B.5.5Fax numberN/AN/AN/A
    B.5.6E-mailmiller.kristi@gene.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name XOLAIR
    D.2.1.1.2Name of the Marketing Authorisation holderGenentech Inc
    D.2.1.2Country which granted the Marketing AuthorisationUnited States
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Powder for solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNOMALIZUMAB
    D.3.9.1CAS number 242138-07-4
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number150
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typemonoclonal antibody anticuerpo monoclonal
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name XOLAIR
    D.2.1.1.2Name of the Marketing Authorisation holderGenentech Inc
    D.2.1.2Country which granted the Marketing AuthorisationUnited States
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Powder for solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNOMALIZUMAB
    D.3.9.1CAS number 242138-07-4
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number150
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typemonoclonal antibody anticuerpo monoclonal
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name XOLAIR
    D.2.1.1.2Name of the Marketing Authorisation holderGenentech Inc
    D.2.1.2Country which granted the Marketing AuthorisationUnited States
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Powder for solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNOMALIZUMAB
    D.3.9.1CAS number 242138-07-4
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number150
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typemonoclonal antibody anticuerpo monoclonal
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboPowder for solution for injection
    D.8.4Route of administration of the placeboSubcutaneous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    CHRONIC IDIOPATHIC URTICARIA (CIU)
    URTICARIA IDIOPÁTICA CRÓNICA (UIC)
    E.1.1.1Medical condition in easily understood language
    Chronic Itch/Hives without known cause
    Prurito/ronchas crónico/as sin causa conocida
    E.1.1.2Therapeutic area Diseases [C] - Skin and Connective Tissue Diseases [C17]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 14.1
    E.1.2Level PT
    E.1.2Classification code 10021247
    E.1.2Term Idiopathic urticaria
    E.1.2System Organ Class 10040785 - Skin and subcutaneous tissue disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Primary Objective
    To evaluate the efficacy of omalizumab compared with placebo in patients with refractory chronic idiopathic urticaria (CIU) receiving concomitant H1 antihistamine therapy
    Objetivo principal
    Evaluar la eficacia de omalizumab en comparación con el placebo en pacientes con urticaria idiopática
    crónica (UIC) resistente al tratamiento que reciben tratamiento concomitante con antihistamínicos H1.
    E.2.2Secondary objectives of the trial
    Secondary Objectives
    To evaluate the safety of omalizumab therapy in patients with refractory CIU
    To evaluate onset of clinical effect of omalizumab therapy in CIU
    To evaluate the dose of omalizumab therapy in patients with refractory CIU
    To evaluate duration of response after withdrawal of omalizumab in patients with refractory CIU
    To evaluate the quality-of-life benefit of omalizumab therapy in patients with refractory CIU
    Objetivos secundarios
    -Evaluar la seguridad del tratamiento con omalizumab en pacientes con UIC resistente al tratamiento.
    -Evaluar el inicio del efecto clínico del tratamiento con omalizumab en la UIC. -Evaluar la dosis del
    tratamiento con omalizumab en pacientes con UIC resistente al tratamiento. -Evaluar la duración de la
    respuesta después de la retirada de omalizumab en pacientes con UIC resistente al tratamiento.
    -Evaluar el beneficio sobre la calidad de vida del tratamiento con omalizumab en pacientes con UIC
    resistente al tratamiento.
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    DNA REPOSITORY SUBSTUDY IN ASSOCIATION WITH XOLAIR (OMALIZUMAB) STUDY Q4881g
    Date : 24 September 2010
    Version 1
    The primary objective of this study is to perform exploratory analyses to generate hypotheses identifying genes associated with treatment response, toxicity, or disease risk. If such genetic hypotheses are identified, they may be tested in future clinical studies within this therapeutic area.
    SUBESTUDIO DE BANCO DE ADN EN ASOCIACIÓN CON EL ESTUDIO Q4881g DE
    XOLAIR® (OMALIZUMAB) Version 1 Fecha: 24 de Septiembre de 2010 El objetivo principal de
    este estudio es realizar análisis exploratorios para generar hipótesis que identifiquen genes asociados
    con la respuesta al tratamiento, la toxicidad o el riesgo de enfermedad. En caso de identificar dichas
    hipótesis genéticas, éstas podrán analizarse en futuros estudios clínicos dentro de este área terapéutica.
    E.3Principal inclusion criteria
    Patients must meet the following criteria for study entry:
    1. Aged 12-75 years (age limits may vary dependent upon regional restrictions).
    2. Diagnosis of CIU refractory to H1 antihistamines at the time of randomization,
    as defined by all of the following:
    The presence of itch and hives for >=8 consecutive weeks at any time prior
    to enrollment despite current use of H1 antihistamine treatment during this
    time period UAS7 score (range 0-42) >= 16 and itch component of UAS7 (range 0-21) >=8 during 7 days prior to randomization (Week 0) In-clinic UAS>= 4 on at least one of the screening visit days (Day -14, Day - 7 or Day 1) Patients must have been on an approved dose of an H1 antihistamine for CIU for at least the 3 consecutive days immediately prior to the Day -14 screening visit and must document current use on the day of the initial screening visit. CIU diagnosis for >= 6 months.
    3. Willing to give written informed consent, adhere to the visit schedules and meet study requirements.For those patients below the legal age of consent, the child must be willingto give written informed assent and the parent(s)/guardian(s) must be willing to give written informed consent. For patients below the legal age of consent, both child and parent must be able to adhere to dose and visit schedules and meet study requirements.
    4. Willing and able to complete a daily symptom eDiary for the duration of the
    study.
    5. Patients must not have any missing eDiary entries in the 7 days prior to
    randomization.
    Los pacientes deberán cumplir los criterios siguientes para entrar en el estudio: 1.Edad comprendida entre 12 y 75 años (los límites de edad pueden variar dependiendo de las restricciones regionales)
    2.Diagnóstico de UIC resistente a antihistamínicos H1 en el momento de la asignación aleatoria, según lo definido por todo lo siguiente:
    La presencia de prurito y habones durante >=8 semanas consecutivas
    en cualquier momento previo a la inclusión en el estudio a pesar del uso actual de tratamiento con antihistamínicos H1 durante este periodo. Puntuación UAS7 (intervalo 0-42) >=16 y componente de prurito de la UAS7 (intervalo 0-21) >=8 durante los 7 días previos a la asignación aleatoria (semana 0).
    UAS en consulta >=4 en al menos uno de los días de visita de selección (día -14, día -7 o día 1). Los pacientes deben haber estado en tratamiento con una dosis aprobada de un antihistamínico H1 para la UIC durante al menos 3 días consecutivos inmediatamente antes de la visita de selección del día -14 y
    debe documentarse el uso actual en el día de la visita de selección inicial. Diagnóstico de UIC durante >=6 meses.
    3.Voluntad de dar el consentimiento informado por escrito, así como cumplir el programa de visitas y los requisitos del estudio. En el caso de pacientes que no tengan edad legal para dar su consentimiento, el niño debe tener voluntad de dar su asentimiento informado por escrito y los progenitores o tutores deben tener voluntad de dar su consentimiento informado por escrito. En el caso
    de pacientes que no tengan edad legal para dar su consentimiento, tanto el niño como el progenitor deben ser capaces de cumplir con los programas de dosificación y visitas, así como con los requisitos del estudio.
    4.Voluntad y capacidad para rellenar un eDiario de síntomas diariamente durante todo el tiempo que dure el estudio.
    5.Los pacientes no deben tener ninguna omisión en las entradas del eDiario
    en los 7 días previos a la asignación aleatoria.
    E.4Principal exclusion criteria
    Patients who meet any of the following criteria will be excluded from study entry:
    1. Treatment with an investigational agent within 30 days of Day -14.
    2. Weight less than 20 kg (44 lbs).
    3. Clearly defined underlying etiology for chronic urticarias other than CIU (main
    manifestation being physical urticaria). This includes the following urticarias:
    Acute, solar, cholinergic, heat, cold, aquagenic, delayed pressure or contact
    As well as the following diseases as these diseases may have symptoms
    of urticaria or angioedema Urticarial vasculitis, urticaria pigmentosa, erythema multiforme, mastocytosis, hereditary or acquired angioedema, lymphoma, leukemia, or generalized cancer.
    4. Evidence of parasitic infection defined as having the following three items:
    Risk factors for parasitic disease (living in an endemic area, chronic GI symptoms, travel within the last 6 months to an endemic area and/or chronic immunosuppression) AND An absolute eosinophil count more than twice the upper limit of normal AND Evidence of parasitic colonization or infection on stool evaluation for ova and parasites. Note that stool ova and parasite evaluation will only be conducted in patients with both risk factors and an eosinophil count more than twice the upper limit of normal.
    5. Atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus or other skin disease associated with itch.
    6. Previous treatment with omalizumab within a year prior to Day -14.
    7. Routine (daily or every other day during 5 or more consecutive days) doses of the following medications within 30 days prior to Day -14: systemic or cutaneous (topical) corticosteroids (prescription or over the counter), hydroxychloroquine, methotrexate, cyclosporine, or cyclophosphamide.
    8. IV immunoglobulin G (IVIG), or plasmapheresis within 30 days prior to Day -14.
    9. Regular (daily/every other day) doxepin (oral) use within 14 days prior to
    Day -14.
    10. Any H2 antihistamine use within 7 days prior to Day -14.
    11. Any LTRA (montelukast or zafirlukast) within 7 days prior to Day -14.
    12. Any H1 antihistamines at greater than approved doses within 3 days prior to
    Day -14.
    13. Patients with current malignancy, history of malignancy, or currently under
    work-up for suspected malignancy except non-melanoma skin cancer that has
    been treated or excised and is considered resolved.
    14 .Hypersensitivity to omalizumab or any component of the formulation.
    15. History of anaphylactic shock.
    16. Presence of clinically significant cardiovascular, neurological, psychiatric,
    metabolic or other pathological conditions that could interfere with the
    interpretation of the study results and or compromise the safety of the patients.
    17. Medical examination or laboratory findings that suggest the possibility of
    decompensation of co-existing conditions for the duration of the study.
    Any items that are cause for uncertainty must be reviewed with the Medical Monitor.
    18. Inability to comply with study and follow-up procedures.
    19. Evidence of current drug or alcohol abuse.
    20. Nursing women or women of childbearing potential, defined as all women
    physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means, UNLESS they meet the following definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels > 40 mIU/mL or 6 weeks post-surgical bilateral oophorectomy (with or without hysterectomy) or hysterectomy OR are using one or more of the following acceptable methods of contraception: surgical sterilization (e.g., bilateral tubal ligation, vasectomy), hormonal contraception (implantable, patch, oral), and double-barrier methods (any double combination of: IUD, male or female condom with spermicidal gel, diaphragm, sponge, or cervical cap).
    21. Contraindications to diphenhydramine: Overreactivity against the agent
    diphenhydramine, other antihistaminic agents, or other components of this agent; acute bronchial asthma; acute angle-closure glaucoma; pheochromocytoma; hyperplasia of the prostate gland with formation of residual urine; epilepsy; hypokalemia; hypomagnesemia; bradycardia; a congenital long QT syndrome or other clinically significant cardial disorders (especially coronary heart disease, disturbances in conduction, arrhythmias); the simultaneous application of drugs which prolong the QT interval (e.g., antiarrhythmic drugs class IA or III, antibiotics, cisapride, malaria drugs, antihistaminic drugs, neuroleptic drugs) or lead to hypokalemia (e.g., certain diuretic drugs); the simultaneous application of MAO inhibitors; the simultaneous uptake of alcohol.
    Los pacientes que cumplan cualquiera de los siguientes criterios serán excluidos del estudio:
    1.Tratto con un fármaco en investigación en los 30 días previos al día-14.
    2.Peso inferior a 20 kg (44 libras).
    3.Etiología subyacente claramente definida para urticarias crónicas que no sean UIC (siendo la principal manifestación la urticaria física). Esto incluye las siguientes urticarias: Aguda, solar, colinérgica, por calor, por frío, acuagénica, retardada por presión o por contacto. Tanto las siguientes enfermedades
    como estas enfermedades pueden tener los mismos síntomas de urticaria o angioedema. Vasculitis urticariana, urticaria pigmentosa, eritema multiforme, mastocitosis, angioedema hereditario o adquirido, linfoma, leucemia o cáncer generalizado.
    4.Pruebas de infección parasitaria definida como la presencia de los tres elementos siguientes: Factores de riesgo para enfermedad parasitaria (vivir en una zona endémica, síntomas GI crónicos, viaje en los últimos 6 meses a una zona endémica y/o inmunodepresión crónica). Y Un recuento absoluto de eosinófilos de más de dos veces el límite superior normal. Y Pruebas de colonización o infección parasitaria en la evaluación de las heces para huevos o
    parásitos. Téngase en cuenta que la evaluación de huevos o parásitos en las heces solo se realizará en
    pacientes tanto con factores de riesgo como con un recuento de eosinófilos de más de dos veces el límite
    superior normal.
    5.Dermatitis atópica, penfigoide ampolloso, dermatitis herpetiforme, prurito senil u otras enfermedades cutáneas asociadas con prurito.
    6.Tratto previo con omalizumab en el plazo de un año antes del día -14.
    7.Dosis habituales (diarias o cada dos días durante 5 o más días consecutivos) de los siguientes medicamentos en los 30 días previos al día -14: corticoesteroides sistémicos o cutáneos (tópicos) (con o sin receta), hidroxicloroquina, metotrexato, ciclosporina o ciclofosfamida.
    8.Inmunoglobulina G IV (IgGIV) o plasmaféresis en los 30 días previos al día -14.
    9.Uso regular (diariamente/cada dos días) de doxepina (oral) en los 14 días previos al día -14.
    10.Uso de cualquier antihistamínico H2 en los 7 días previos al día -14. 11.Cualquier ARLT (montelukast o zafirlukast) en
    los 7 días previos al día -14.
    12.Cualquier antihistamínico H1 a dosis mayores de las aprobadas en los 3
    días previos al día -14.
    13.Los pacientes con una neoplasia maligna actual, antecedentes de neoplasia
    maligna o actualmente bajo pruebas diagnósticas por sospecha de neoplasia maligna, excepto cáncer cutáneo no melanoma que se ha tratado o extirpado y se considera curado.
    14.Hipersensibilidad a omalizumab o a cualquier componente de la formulación. 15.Antecedentes de choque anafiláctico.
    16.Presencia de enfermedad cardiovascular, neurológica, psiquiátrica, metabólica o cualquier otra clínicamente significativa que pudiera interferir con la interpretación de los resultados del estudio y/o comprometer la seguridad de los pacientes.
    17.Examen médico o resultados analíticos que sugieran la posibilidad de descompensación de enfermedades coexistentes durante el estudio. Cualquier elemento que sea causa de incertidumbre debe ser revisado por el monitor clínico.
    18.Incapacidad para cumplir los procedimientos del estudio y del seguimiento. 19.Indicios de toxicomanía o alcoholismo actual.
    20.Las mujeres en periodo de lactancia o las mujeres en edad fértil, definidas como todas las mujeres fisiológicamente capaces de quedarse embarazadas, incluyendo mujeres cuya carrera, estilo de vida u orientación sexual imposibilite las relaciones sexuales con una pareja sexual masculina y las mujeres
    cuya pareja se ha esterilizado mediante vasectomía u otro medio, SALVO que cumplan la siguiente definición de posmenopáusica: 12 meses de amenorrea natural (espontánea) o 6 meses de amenorrea espontánea con niveles séricos de FSH > 40 mUI/ml o 6 semanas tras ovariectomía lateral (con o sin histerectomía) o histerectomía O estén usando uno o más de los siguientes métodos anticonceptivos aceptables: esterilización quirúrgica (por ejemplo, ligadura de trompas bilateral, vasectomía), anticonceptivo hormonal (implantable, en parche, oral), y métodos de doble barrera (cualquier combinación doble de: DIU, preservativo masculino o femenino con gel espermicida, diafragma,
    esponja o capuchón cervical).
    21.Contraindicaciones a la difenhidramina: reactividad excesiva contra el
    agente difenhidramina, otros agentes antihistamínicos u otros componentes de este agente; asma bronquial aguda; glaucoma agudo de ángulo cerrado; feocromocitoma; hiperplasia de la glándula prostática con formación de orina residual; epilepsia; hipocalemia; hipomagnesemia; bradicardia; síndrome de QT largo congénito u otra cardiopatía clínicamente significativa (especialmente cardiopatía coronaria, alteraciones en la conducción, arritmias); la aplicación simultánea de fármacos que prolongan el intervalo de QT (por ejem...
    E.5 End points
    E.5.1Primary end point(s)
    The primary efficacy endpoint is the change in weekly itch score from baseline to Week 12. The analysis of the primary endpoint will consist of treatment comparisons made using analysis of covariance (ANCOVA) controlling for baseline weekly itch score, and baseline weight (less than 80 kg vs. more than or equal to 80 kg). The ANCOVA model will be based on the mITT patients. Missing Week 12 itch scores will be imputed by carrying forward the patients baseline scores (BOCF). The Week 12 itch scores for patients who received excluded therapy listed in Section 4.4.2 by Week 12 will also be imputed using their baseline scores.
    El criterio principal de valoración de la eficacia es el cambio en la puntuación semanal de prurito desde el inicio del estudio hasta la semana 12. El análisis del criterio principal de valoración consistirá en comparaciones entre tratamientos realizadas mediante el análisis de covarianza (ANCOVA) controlando la puntuación semanal de prurito inicial y el peso inicial (< 80 kg frente a >= 80 kg). El modelo ANCOVA se basará en la población de pacientes mITT. Las puntuaciones de prurito de la semana 12 omitidas serán atribuidas considerando las puntuaciones iniciales de los pacientes (BOCF). Las puntuaciones de prurito de la semana 12 de pacientes que reciban un tratamiento excluido de los enumerados en la sección 4.4.2 también se atribuirán usando sus puntuaciones iniciales.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Week 12
    Semana 12
    E.5.2Secondary end point(s)
    As CIU is both a disease of hives and intense itch, it is appropriate to evaluate clinical response using a composite endpoint, UAS, which incorporates both of these symptoms and this will be incorporated as a secondary endpoint.

    Secondary Endpoints

    1. Change from baseline in UAS7 at Week 12

    2. Time to weekly itch score MID response by Week 12

    3. Proportion of patients with UAS7 <=6 at Week 12

    4. Change from baseline in weekly hive score at Week 12

    5. Change from baseline in weekly largest hive score at Week 12

    6. Proportion of weekly itch score MID responders at Week 12

    7. Proportion of patients with UAS7 <=6 at Week 40

    8. Change from baseline in health-related quality of life as measured by the DLQI at Week 12

    9. Proportion of angioedema-free days from Week 4 to Week 12 of therapy
    Puesto que la UIC es una enfermedad que se manifiesta tanto con habones como con prurito intenso, es apropiado evaluar la respuesta clínica usando un criterio de valoración compuesto, la UAS, que incorpora ambos síntomas, por lo que se incluirá como criterio de valoración secundario.

    Criterios Secundarios

    1. Cambio respecto al valor inicial en la UAS7 a la semana 12
    2. Tiempo hasta la respuesta de diferencia mínimamente importante (DMI) en la puntuación semanal de prurito a la semana 12
    3. Proporción de pacientes con UAS7 < o = 6 en la semana 12
    4. Cambio respecto al valor inicial en la puntuación semanal de habones en la semana 12
    5. Cambio respecto al valor inicial en la puntuación semanal del habón más grande en la semana 12
    6. Proporción de pacientes con respuesta de DMI en la puntuación semanal de prurito en la semana 12
    7. Proporción de pacientes con UAS7 < o = 6 en la semana 40
    8. Cambio respecto al valor inicial en la calidad de vida relacionada con la salud determinada mediante el Índice de calidad de vida en dermatología (DLQI) en la semana 12
    9. Proporción de días sin angioedema desde la semana 4 a la semana 12 de tratamiento
    E.5.2.1Timepoint(s) of evaluation of this end point
    Week 12, Week 40
    Semana 12, semana 40
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial4
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned4
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA26
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Russian Federation
    Turkey
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of the study is defined as the last enrolled patient?s last visit.
    El fin de ensayo de define como último paciente incluido última visita.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years0
    E.8.9.1In the Member State concerned months10
    E.8.9.1In the Member State concerned days14
    E.8.9.2In all countries concerned by the trial years0
    E.8.9.2In all countries concerned by the trial months10
    E.8.9.2In all countries concerned by the trial days14
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 1
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 1
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 10
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 2
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state13
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 101
    F.4.2.2In the whole clinical trial 301
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Ninguna información
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2011-10-07
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2011-05-20
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2012-10-17
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 05:19:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA